Recce Pharmaceuticals (ASX:RCE) has successfully obtained its first patent for its flagship anti-infective drug R327 in Israel.
The State of Israel Patent Office ticked off on patent #295116 under ‘Patent Family 4.’ The patent expires in 2041.
Recce’s flagship R327 drug has been approved for patent along with Recce 529 (R529).
The israeli patent effectively permits Recce to claim legal rights to the drug, its manufacture, and its distribution in the jurisdiction.
Both drugs will focus on bacterial infections and viral infections which the company hopes will produce further data validating the use of its drugs in a variety of conditions.
Those conditions include burn wounds, UTIs, the STI gonorrhoea, the flu, and even COVID. As for bacteria, E.coli and staph are among target conditions for Recce.
“Israel’s pharmaceuticals and biotech market has a reputation for high R&D spending,” the company said on Wednesday, highlighting the country’s healthcare spend in 2020 of 8.3% of GDP.
The company also highlighted figures from the Israeli stats office that the elderly population will grow by 77% to reflect 14.3% of the population at the start of 2040.
Recce shares were up 2.27% to 45cps at 10.30am AEDT.